Home

CARB-X is accelerating global antibacterial innovation by investing in the development of new antibiotics and other life-saving products to combat the most dangerous drug-resistant bacteria. Our projects represent the world’s largest pre-clinical and early development pipeline of antibiotics and other therapeutics, diagnostics, microbiome, vaccines, and devices.

85+

$million

Invested

30+

company

Projects

7

different

Countries

9

new antibiotic classes in

Pipeline

The Challenge

Accelerate the development of novel antibiotics and other new approaches to address the emergence of drug-resistant superbugs.
Learn More


Spotlight on Science

Vedanta is fighting superbugs by boosting the body’s own microbiome.

Learn More

“Antibiotics transformed modern medicine but overuse and inappropriate use have led to dangerous bacteria developing deadly resistance. Drug discovery must go hand-in-hand with concerted action to ensure antibiotics of last resort are reserved for patients where first-line treatments will not work. And we must ensure these treatments are available in all countries for those who need them.”

— Tim Jinks
Head of Drug Resistant Infections
Wellcome Trust

Funders

ASPR
BARDA
WellcomeTrust
NIAID
UK Government

Alliance Partners

Bill and Melinda Gates Foundation

Accelerators

Boston University
RTI
CLSI
MassBio
Broad Institute
DTRA

Events

Events

08.20.18

Washington, DC

Next Generation Dx Summit: Investment Plenary Panel

09.04.18

Lisbon, Portugal

ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance

10.23.18

Geneva, Switzerland

Fostering Investment in the Development of New Antibacterial Treatments - UNCTAD World Investment Forum

CARB-X News

  • 05.22.2018  |  UK Government and Bill & Melinda Gates Foundation join CARB-X partnership in fight against superbugs full release

  • 05.15.2018  |  CARB-X funds MicrobeDx to support development of a transformative testing system to rapidly diagnose life-threatening infections in the urinary tract full release

  • 05.10.2018  |  CARB-X funds Talis Biomedical to develop systems to diagnose chlamydia and gonorrhea within minutes and determine which antibiotics would kill the bacteria full release

See All News

In The News

  • 06.08.2018  |  An Unlikely Biotech Investor: The Government full story

  • 05.31.2018  |  Dept. of Existential threats. Who’s worried about Superbugs? full story

  • 05.22.2018  |  By 2050 one person will die every three seconds if we don’t tackle antibiotic resistance full story

See All News

Sign up for CARB-X news

Get the latest news and announcements from CARB-X.